Showing 1 - 10 results of 10 for search 'Jeffry Evans, T', query time: 0.03s
Refine Results
-
1
A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in... by Leijen, S, Soetekouw, P, Jeffry Evans, T, Nicolson, M, Schellens, J, Learoyd, M, Grinsted, L, Zazulina, V, Pwint, T, Middleton, M
Published 2011Journal article -
2
A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in... by Leijen, S, Soetekouw, P, Jeffry Evans, T, Nicolson, M, Schellens, J, Learoyd, M, Grinsted, L, Zazulina, V, Pwint, T, Middleton, M
Published 2011Journal article -
3
-
4
Characterization of Tumor Responses in Patients With Unresectable Hepatocellular Carcinoma Treated With Lenvatinib in the Phase 3 Randomized Trial, REFLECT by Richard S. Finn, Shukui Qin, Fabio Piscaglia, Thomas R Jeffry Evans, Jennifer J. Knox, Carlos López López, Zahra Ramji, Min Ren, Kalgi Mody, Arndt Vogel, Masatoshi Kudo
Published 2024-02-01
Article -
5
Impact of the COVID-19 pandemic on patients with hepatocellular carcinoma in the West of Scotland: a cohort study by Douglas Cartwright, Stephen Barclay, Adrian Stanley, Neil Lachlan, Ruth Gillespie, Ewan Forrest, Matthew Priest, Andrew Fraser, Michael Johnston, Gregory Naylor, Umberto Pisano, David Kay, Ram Kasthuri, Stuart Ballantyne, Heather Lafferty, Jeffry Evans, Karin Oien, Alistair Stewart McLaren, Johannes A Spoor, Srikanth Puttagunta, Kirsty Armstrong, Thomas R Jeffry Evans, Shouren Datta, Jennifer Milne, Rachel Swann, Adam Wimpress
Published 2023-11-01
Article -
6
Liquid Biopsy for Pancreatic Cancer Detection Using Infrared Spectroscopy by Alexandra Sala, James M. Cameron, Cerys A. Jenkins, Hugh Barr, Loren Christie, Justin J. A. Conn, Thomas R. Jeffry Evans, Dean A. Harris, David S. Palmer, Christopher Rinaldi, Ashton G. Theakstone, Matthew J. Baker
Published 2022-06-01
Article -
7
SPIRIT and CONSORT extensions for early phase dose-finding clinical trials: the DEFINE (DosE-FIndiNg Extensions) study protocol by Sally Hopewell, An-Wen Chan, Christopher Weir, Adrian Mander, Rong Liu, Christina Yap, Johann De Bono, Khadija Rantell, Munyaradzi Dimairo, Thomas Jaki, Alun Bedding, Aude Espinasse, Olga Solovyeva, Andrew Kightley, Jeffry Evans, Shing Lee
Published 2023-03-01
Article -
8
A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301) by Pavlina Spiliopoulou, Farasat Kazmi, Francesca Aroldi, Thomas Holmes, David Thompson, Lucinda Griffiths, Cathy Qi, Matthew Parkes, Simon Lord, Gareth J. Veal, David J. Harrison, Vicky M. Coyle, Jill Graham, Thomas R. Jeffry Evans, Sarah P. Blagden
Published 2024-04-01
Article -
9
Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study by Jessica C Hassel, Mark R Middleton, Alexander N Shoushtari, Omid Hamid, Paolo A Ascierto, Todd M Bauer, John M Kirkwood, Friedegund Meier, Marlana Orloff, Paul C Lorigan, Chris Holland, Cornelia Mauch, Ramakrishna Edukulla, April K S Salama, Thomas R Jeffry Evans, Shaad E Abedin
Published 2023-06-01
Article -
10
Development of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE study by Olga Solovyeva, Munyaradzi Dimairo, Christopher J. Weir, Siew Wan Hee, Aude Espinasse, Moreno Ursino, Dhrusti Patel, Andrew Kightley, Sarah Hughes, Thomas Jaki, Adrian Mander, Thomas R. Jeffry Evans, Shing Lee, Sally Hopewell, Khadija Rerhou Rantell, An-Wen Chan, Alun Bedding, Richard Stephens, Dawn Richards, Lesley Roberts, John Kirkpatrick, Johann de Bono, Christina Yap
Published 2023-07-01
Article